Zoetis Inc. (NYSE:ZTS) Shares Sold by Woodline Partners LP

Woodline Partners LP reduced its stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 90.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 17,148 shares of the company's stock after selling 160,394 shares during the quarter. Woodline Partners LP's holdings in Zoetis were worth $2,794,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of ZTS. JPMorgan Chase & Co. boosted its holdings in Zoetis by 10.6% during the third quarter. JPMorgan Chase & Co. now owns 2,916,539 shares of the company's stock worth $569,834,000 after buying an additional 279,092 shares in the last quarter. Janney Montgomery Scott LLC raised its position in shares of Zoetis by 65.7% in the fourth quarter. Janney Montgomery Scott LLC now owns 172,111 shares of the company's stock worth $28,042,000 after acquiring an additional 68,227 shares during the period. Mutual Advisors LLC boosted its stake in shares of Zoetis by 31.4% during the 4th quarter. Mutual Advisors LLC now owns 3,691 shares of the company's stock worth $625,000 after acquiring an additional 882 shares in the last quarter. Secure Asset Management LLC grew its position in shares of Zoetis by 39.8% during the 4th quarter. Secure Asset Management LLC now owns 2,297 shares of the company's stock valued at $374,000 after acquiring an additional 654 shares during the period. Finally, Brighton Jones LLC grew its position in shares of Zoetis by 180.4% during the 4th quarter. Brighton Jones LLC now owns 4,629 shares of the company's stock valued at $754,000 after acquiring an additional 2,978 shares during the period. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have commented on the company. Barclays raised their price objective on Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a report on Friday, February 14th. UBS Group cut their price objective on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a research report on Wednesday, May 7th. Wall Street Zen upgraded shares of Zoetis from a "hold" rating to a "buy" rating in a report on Friday, March 7th. Piper Sandler upped their price objective on Zoetis from $205.00 to $210.00 and gave the company an "overweight" rating in a report on Monday, May 12th. Finally, Morgan Stanley cut their target price on Zoetis from $243.00 to $238.00 and set an "overweight" rating for the company in a research note on Friday, February 14th. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, Zoetis has a consensus rating of "Buy" and an average price target of $212.75.

Insider Buying and Selling

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the business's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $170.00, for a total transaction of $55,420.00. Following the completion of the transaction, the executive vice president now owns 15,781 shares in the company, valued at $2,682,770. The trade was a 2.02% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Willie M. Reed sold 1,210 shares of Zoetis stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total transaction of $201,029.40. Following the sale, the director now directly owns 11,245 shares of the company's stock, valued at approximately $1,868,244.30. This trade represents a 9.71% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.18% of the stock is currently owned by insiders.

Zoetis Trading Down 0.6%

Zoetis stock traded down $1.06 during midday trading on Wednesday, reaching $165.20. 1,723,724 shares of the stock traded hands, compared to its average volume of 2,524,637. The firm has a market cap of $73.55 billion, a PE ratio of 30.20, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. The company has a 50-day simple moving average of $156.53 and a two-hundred day simple moving average of $164.69. Zoetis Inc. has a 12-month low of $139.70 and a 12-month high of $200.33.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported $1.48 EPS for the quarter, beating the consensus estimate of $1.40 by $0.08. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The business had revenue of $2.22 billion during the quarter, compared to analyst estimates of $2.20 billion. During the same quarter last year, the firm posted $1.38 earnings per share. The business's revenue for the quarter was up 1.4% compared to the same quarter last year. Research analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Friday, July 18th will be issued a $0.50 dividend. The ex-dividend date is Friday, July 18th. This represents a $2.00 dividend on an annualized basis and a yield of 1.21%. Zoetis's dividend payout ratio (DPR) is presently 35.91%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.